Modus Therapeutics Holding AB Stock price

Equities

MODTX

SE0015987904

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:38:47 2024-03-28 am EDT 5-day change 1st Jan Change
1.14 SEK +1.33% Intraday chart for Modus Therapeutics Holding AB -9.16% -34.29%
Sales 2024 * - Sales 2025 * - Capitalization 40.97M 438M
Net income 2024 * -27M -289M Net income 2025 * -37M -396M EV / Sales 2024 * -
Net cash position 2024 * 13M 139M Net cash position 2025 * 47M 503M EV / Sales 2025 * -
P/E ratio 2024 *
-1.5 x
P/E ratio 2025 *
-1.08 x
Employees 2
Yield 2024 *
-
Yield 2025 *
-
Free-Float 9.89%
More Fundamentals * Assessed data
Dynamic Chart
Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan MT
Modus Therapeutics Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Modus Therapeutics Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Modus Therapeutics Announces Positive Topline Data from Phase 1b LPS Provocation Study Evaluating the Potential of Sevuparin for Treatment of Sepsis CI
Modus Therapeutics Files Patent Application for Kidney Disease Drug MT
Modus Therapeutics Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Modus Therapeutics Holding AB Completes Recruitment for Phase 1B LPS Provocation Study CI
Modus Therapeutics Holding AB Announces First Patient Enrolled in the Phase I SEVUSMART Clinical Trial Evaluating Sevuparin in Paediatric Patients with Severe Malaria CI
Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Certain Shares of Modus Therapeutics Holding AB are subject to a Lock-Up Agreement Ending on 22-JUL-2022. CI
Certain Shares of Modus Therapeutics Holding Ab are subject to a Lock-Up Agreement Ending on 22-JUL-2022. CI
Modus Therapeutics Updates on Sevuparin Phase 1b Clinical Trial Timelines CI
More news
1 day+1.33%
1 week-9.16%
Current month-32.74%
1 month-33.33%
3 months-34.48%
6 months-42.42%
Current year-34.29%
More quotes
1 week
1.02
Extreme 1.02
1.27
1 month
1.02
Extreme 1.02
1.74
Current year
1.02
Extreme 1.02
2.52
1 year
1.02
Extreme 1.02
3.60
3 years
1.02
Extreme 1.02
7.10
5 years
1.02
Extreme 1.02
7.10
10 years
1.02
Extreme 1.02
7.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 19-12-31
Director of Finance/CFO 57 21-03-14
Director/Board Member 50 -
Members of the board TitleAgeSince
Chairman 59 15-12-31
Director/Board Member 65 13-12-31
Director/Board Member 50 -
More insiders
Date Price Change Volume
24-03-28 1.14 +1.33% 36 360
24-03-27 1.125 +1.35% 5,989
24-03-26 1.11 -1.77% 35,099
24-03-25 1.13 -9.24% 52,111
24-03-22 1.245 -0.80% 162,762

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:38 am EDT

More quotes
Modus Therapeutics Holding AB is a Sweden-based biotechnology company that develops sevuparin for severe diseases with large residual medical needs. The company's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Modus Therapeutics Holding AB - Nasdaq Stockholm